Genmab A/S (LTS:0MGB)
kr 1839.5 -9.25 (-0.5%) Market Cap: 117.16 Bil Enterprise Value: 88.58 Bil PE Ratio: 22.03 PB Ratio: 3.66 GF Score: 84/100

Genmab A/S Virtual R&D Update and ASH Data Review Transcript

Dec 14, 2021 / 07:00PM GMT
Release Date Price: kr2405 (-4.24%)
Jan G.J. van de Winkel;S;Co;Founder
Genmab A;President & CEO

/-- -

(technical difficulty) for the safety and convenience of both you our audience and our speakers, we have once again gone virtual for this year's R&D update and ASH data review. And as always, we have a busy agenda, so let's begin.

Please move to Slide 2. As a reminder, this presentation may contain forward-looking statements and as such, may contain certain risks and uncertainties.

Let's move to Slide 3. Genmab has a science focus and innovation-based culture and collaborations and partnerships have always been part of our DNA. During today's presentation, we will reference some of the products being developed under these strategic collaborations and this slide acknowledges those relationships.

Let's move to Slide 4. We will kick off this year's event with a review of some of the exciting events of the past year, both within our own portfolio and the ways in which our innovation has been applied to programs of pharma companies. You will then see

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot